Newsroom
Sorted by: Latest
-
The Wella Company Announces Key Leadership Changes to Support Strategic Priorities Across Brand Building, Marketing, Innovation, and Supply Chain
NEW YORK--(BUSINESS WIRE)--The Wella Company Announces Key Leadership Changes to Support Strategic Priorities Across Brand Building, Marketing, Innovation, and Supply Chain...
-
Balyasny Asset Management LP UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, t...
-
Balyasny Asset Management LP UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be...
-
Roth’s Sea & Steak Welcomes the James Beard Foundation® to Colorado Springs for Celebrating Land & Sea, A Friends of James Beard Benefit®
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Venu Holding Corporation (“VENU” or the “Company”) (NYSE AMERICAN: VENU), an owner, operator, and developer of premium live entertainment destinations, today celebrated the success of Celebrating Land & Sea, A Friends of James Beard Benefit®, hosted October 9 and 10 at the Company’s Roth’s Sea & Steak in Colorado Springs. The two-night benefit was the largest culinary event in the restaurant’s history and marked a milestone for Roth’s Sea &...
-
Balyasny Asset Management LP UK Regulatory Announcement: Form 8.3 Tate & Lyle plc
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be...
-
Balyasny Asset Management LP UK Regulatory Announcement: Form 8.3 Rotork plc
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be...
-
Balyasny Asset Management LP UK Regulatory Announcement: Form 8.3 Mitie Group plc
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be...
-
Star Therapeutics Announces $200 Million Private Financing to Advance Pipeline of Best-in-Disease Therapies
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced a $200 million private financing. The financing follows the July 2026 acquisition of Star subsidiary Vega Therapeutics and was co-led by OrbiMed and Janus Henderson Investors, with participation from Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Vent...
-
Foundation Medicine’s FoundationOne®MRD Named a 2026 Top Innovation Winner by The Scientist
BOSTON--(BUSINESS WIRE)--Foundation Medicine's molecular residual disease (MRD) assay, FoundationOne®MRD, has been named a 2026 Top Innovation by The Scientist....
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust IPOX Europe Equity Opportunities UCITS ETF 22.10.2026 IPXE.IM IE00BFD26097 50,002.00 EUR 1,195,577.64 23.911 ...